Drugs / SYH9056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06771245 | Jan 2025 → Mar 2026 overdue | essential hypertension | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS) irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR VALSARTAN AND LEVAMLODIPINE MALEATE TABLETS (SYH9056 TABLETS) irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH9056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06771245 ↗ |
| Route | Oral | “PO once daily, 1 tablet each time” NCT06771245 ↗ |